Merit Medical, a medical device company based out of South Jordan, Utah, announced this week that it has received 510(k) clearance from the FDA for its Corvocet Biopsy System.
The Corvocet Biopsy System was developed for obtaining core biopsy samples from the liver, kidney, prostate, breast, lung, and other soft tissue tumors.
"The Corvocet Biopsy System is Merit’s first entry into the biopsy market and is the first of several biopsy devices we expect to introduce in the future," Fred P. Lampropoulos, Merit chairman and CEO, said in a prepared statement.
Merit said in its statement the system is scheduled to be introduced in the United States “over the next thirty days or so.” A European release will follow once it receives the CE mark.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.